<i>In vitro</i> models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of <scp>CRISPR</scp> perturbations
Elysia C. Saputra(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aleksandra Olow(Amgen (United States)), Suchitra Natarajan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Khoa Dang P. Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex M. Tamburino(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lixia Li(Jilin Agricultural University), Xin Yu(Jiangnan University), Federica Piccioni(Broad Institute), Hong Sun(Fujian Medical University), Shamsudheen Karuthedath Vellarikkal(Broad Institute)
Cited by 1